News
LCT granted diabetes patent in the US
July 5, 2006
Living Cell Technologies (ASX:LCT) has received a Notice of Allowance for a US patent relating to methods of preparing transplantable neo-natal porcine islets, for the treatment of diabetes.
The patent, titled Preparation and Xenotransplantation of Porcine Islets (US 09/857325, Confirmation No 3318), extends LCT's coverage in treating type 1 diabetic patients with its DiabeCell product. The patent claims are to methods of preparing islets and the treatment of diabetes.
Collectively these are broad patent claims for the treatment of diabetes using xenotransplantation (animal cell transplants).
Related Document
Download ( =
53Kb )
|